Over the past year, multiple proposals addressing drug pricing have emerged at both the state and national levels.  While the end goal is lower costs for payors, provider and patients through greater pricing transparency and more efficient distribution models, these complex changes could have far-reaching implications for hospital pharmacy administration and operations.  This session will dive into the pricing proposals in play and will include discussion of the CMS Pricing Transparency Rule, CMS International Pricing Index model, 340B Program Ceiling Price Rule, and the California Executive Order to reduce state drug costs, among others.

Learning Objectives:

1. Discuss the potential impact new pricing proposals and rules may have on Medicare and Medicaid reimbursement for hospitals.
2. Compare and contrast the components of the various proposals and rules.
3. Discuss the importance of hospital-specific analytics when preparing for these proposals and rules.